---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-059386"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T21:03:50.497837+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte Q3 net loss $92.7M; FDA clears VAX-31 IND; VAX-24 Phase 3 agreed

## Summary
- Net loss $92.7M vs $57.9M YoY; cash $1.43B (up from $957.9M Dec 2022).
- Completed End-of-Phase 2 FDA meeting for VAX-24 adult Phase 3; topline data expected 2025.
- FDA cleared VAX-31 adult IND; Phase 1/2 starts Q4 2023, topline data H2 2024.
- Expanded Lonza collaboration for commercial manufacturing of VAX-24 and VAX-31.
- VAX-24 infant Phase 2 advanced to Stage 2 with comparator Prevnar 20.

## SEC filing metadata
- accession: 0000950170-23-059386
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000095017023059386/0000950170-23-059386-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000095017023059386/pcvx-20231106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-059386
- JSON: https://secwatch.observer/filing/0000950170-23-059386.json
- Plain text: https://secwatch.observer/filing/0000950170-23-059386.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.